Article Figures & Data
Figures
- Figure 1
- Comparison of height velocity measurements by gender across sequential time intervals in patients receiving weekly somapacitan therapy.
- Figure 2
- Longitudinal changes in serum insulin-like growth factor-1 levels over 72 weeks for treatment-naive patients compared to patients switched from daily growth hormone therapy.
Tables
- Table 1
- Height velocity by gender across various intervals in patients receiving somapacitan therapy.
Intervals Female Male P-values 12 weeks 8.82±5.23 8.96±5.15 0.800 24 weeks 8.05±3.95 8.58±3.72 0.499 36 weeks 8.91±3.65 8.73±2.56 0.831 72 weeks 7.83±5.80 7.88±1.73 0.603 Values are presented as mean ± standard deviation (SD).
- Table 2
- Height velocity comparison between naive and switched patients across different intervals.
Intervals Naive Switched P-values 12 weeks 9.52±5.18 7.64±4.95 0.018 24 weeks 9.06±3.84 7.33±3.47 0.010 36 weeks 8.76±3.09 8.88±2.78 0.950 72 weeks 8.33±3.45 7.00±2.83 0.883 Values are presented as mean ± standard deviation (SD).
- Table 3
- Changes in insulin-like growth factor-1 levels between treatment-naive patients and patients switched from daily growth hormone therapy over specified intervals.
Time Naive Switched Baseline 152.82±70.62 202.86±131.62 12 weeks 277.71±106.25 306.45±117.40 24 weeks 276.44±111.61 332.59±135.89 36 weeks 300.01±94.57 348.46±129.67 72 weeks 405.26±60.13 456.85±17.32 Values are presented as mean ± standard deviation (SD).
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.